Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. (Annals of oncology : official journal of the European Society for Medical Oncology, 2025)